Revenue Execution Made Clear for Pharma Manufacturers

Pharmaceutical manufacturers are unknowingly leaking as much as 6% of their revenue due ineffective systems used to manage complex pricing, rebating and regulatory processes. That’s $60 million in revenue leakage for every billion dollars under management. 

Get clarity in 2020 and beyond by learning actionable strategies to eliminate revenue leakage and compliance risk, while enabling profitable revenue growth in all channels.

Get Your Free Revenue Execution Assessment

Schedule a Free Revenue Execution Assessment to Receive a Complimentary Report with Insights to Help You:

  • 1 Compare your price management and revenue processes with industry best practices
  • 2 Identify your biggest areas of revenue leakage
  • 3 Quantify your revenue improvements for 2020
  • 4 Set a clear path to maximizing revenue this year

Price Waterfall Explained for Pharma

pharma-thumb

The supply chain for drugs, biologics and medical devices is very complex and without proper management, pharma companies are losing as much as 6% of revenue in overpayments, fees, and inaccurate pricing. The price waterfall shows the elements that affect profitability between base to list price through a manufacturer’s pocket margin. Understanding the full picture is key to finding ways to stop revenue leakage and grow your top line.

Explore the Resources Below to Learn More

Whitepaper Whitepaper
Whitepaper

Guide to Revenue Execution for Pharmaceutical Manufacturers

The global pharmaceutical industry is facing complex and challenging market dynamics t ...

Webinar Webinar
Webinar

Webinar: Life Sciences Predictions for 2020

Join IDC and Model N to learn about evolving trends, market developments, and gain ins ...

Blog Blog
Blog

2020 State of Revenue Report: 95% of companies are leaking revenue

Despite recent advances in technology, particularly around data and analytics, 95% of companies are leaking revenue, and 82% of executives...

Blog Blog
Blog

Meeting the Three Biggest Challenges of Pharma Value-Based Agreements

By Erica Bartlett, Product Manager Value-based agreements (VBAs), sometimes called outcomes-based agreements, are on the rise. According to Aetna, it is estimated...

Whitepaper Whitepaper
Whitepaper

Revenue Management in Life Sciences: The Benefits of a Cloud Computing and SaaS Approach

Download the analyst connection to get IDC’s SaaS insights to help you navigate your r ...

Datasheet Datasheet
Datasheet

Validata

Model N’s Validata solution utilizes cloud-based technology to offer automated script- ...

Blog Blog
Blog

Bringing clarity to pharma compliance

By Kelly Walter, Vice President of Sales, Life Sciences, Model N Are you paying just what you owe on government...

Blog Blog
Blog

Bringing Clarity to Pharma Pricing

By: Jesse Mendelsohn, Vice President | Model N As the election season heats up in the U.S., the debate surrounding...

Blog Blog
Blog

For Accuracy in Pharma Revenue, Head to the Cloud

By Melonie Warfel, VP General Manager, Life Sciences According to IDC, life sciences (pharma and biotech) organizations lose about 4%...

Get your Free Revenue Execution Assessment

Get Your Free Revenue Execution Assessment